Silexion Therapeutics Files 8-K, Former Biomotion Sciences

Ticker: SLXNW · Form: 8-K · Filed: Jul 16, 2025 · CIK: 2022416

Sentiment: neutral

Topics: corporate-action, financials, warrants

Related Tickers: SLXN

TL;DR

Silexion (fka Biomotion) filed an 8-K on 7/16/25, showing warrants at $10.35.

AI Summary

Silexion Therapeutics Corp. filed an 8-K on July 16, 2025, reporting on other events and financial statements. The company, formerly known as Biomotion Sciences until May 6, 2024, is incorporated in the Cayman Islands and has its principal executive offices in Ramat-Gan, Israel. The filing also lists warrants exercisable for ordinary shares at $10.350 per share.

Why It Matters

This 8-K filing provides an update on Silexion Therapeutics' corporate structure and financial reporting, including details on outstanding warrants, which could impact existing shareholders and potential investors.

Risk Assessment

Risk Level: low — The filing is a routine corporate update and does not appear to contain significant negative or positive news that would immediately impact the company's risk profile.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Silexion Therapeutics Corp?

The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of July 16, 2025.

When did Silexion Therapeutics Corp. change its name from Biomotion Sciences?

The company changed its name from Biomotion Sciences on May 6, 2024.

What is the exercise price for the warrants mentioned in the filing?

The warrants are exercisable for ordinary shares at an exercise price of $10.350 per share.

Where are Silexion Therapeutics Corp.'s principal executive offices located?

The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.

What is the SIC code for Silexion Therapeutics Corp?

The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing